MA26522A1 - Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes. - Google Patents

Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.

Info

Publication number
MA26522A1
MA26522A1 MA25173A MA25173A MA26522A1 MA 26522 A1 MA26522 A1 MA 26522A1 MA 25173 A MA25173 A MA 25173A MA 25173 A MA25173 A MA 25173A MA 26522 A1 MA26522 A1 MA 26522A1
Authority
MA
Morocco
Prior art keywords
treatment
pharmaceutical composition
related conditions
sugar diabetes
diabetes
Prior art date
Application number
MA25173A
Other languages
English (en)
Inventor
Dr Robin Edwin Buckingham
Dr Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26522A1 publication Critical patent/MA26522A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
MA25173A 1997-07-18 1998-07-16 Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes. MA26522A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715306A GB9715306D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
MA26522A1 true MA26522A1 (fr) 2004-12-20

Family

ID=10816177

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25173A MA26522A1 (fr) 1997-07-18 1998-07-16 Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.

Country Status (41)

Country Link
EP (1) EP0998291B2 (fr)
JP (2) JP2001510158A (fr)
KR (1) KR100680667B1 (fr)
CN (1) CN1264302A (fr)
AP (1) AP1318A (fr)
AR (2) AR016768A1 (fr)
AT (1) ATE366577T1 (fr)
AU (1) AU743269B2 (fr)
BG (1) BG64892B1 (fr)
BR (1) BR9810904A (fr)
CA (1) CA2297115C (fr)
CO (1) CO4940422A1 (fr)
CY (1) CY1107745T1 (fr)
CZ (1) CZ302668B6 (fr)
DE (1) DE69838066T3 (fr)
DK (1) DK0998291T4 (fr)
DZ (1) DZ2564A1 (fr)
EA (1) EA003303B1 (fr)
ES (1) ES2290989T5 (fr)
GB (1) GB9715306D0 (fr)
HK (1) HK1029272A1 (fr)
HU (1) HU229119B1 (fr)
ID (1) ID24198A (fr)
IL (1) IL134045A0 (fr)
IN (1) IN189035B (fr)
MA (1) MA26522A1 (fr)
MY (1) MY138246A (fr)
NO (1) NO326356B1 (fr)
NZ (3) NZ520652A (fr)
OA (1) OA11632A (fr)
PE (1) PE99799A1 (fr)
PL (2) PL338127A1 (fr)
PT (1) PT998291E (fr)
SI (1) SI0998291T2 (fr)
SK (2) SK287823B6 (fr)
TR (1) TR200000135T2 (fr)
TW (1) TW586926B (fr)
UA (1) UA70302C2 (fr)
UY (1) UY25103A1 (fr)
WO (1) WO1999003476A1 (fr)
ZA (1) ZA986365B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832291A3 (fr) * 1999-07-13 2009-11-04 Medicure Inc. utilisation de pyridoxal phosphate pour le traitement du diabete
EP1897547A1 (fr) * 1999-07-13 2008-03-12 Medicure Inc. Utilisation de dérivés de phosphate de pyridoxal dans le traitement du diabète et de ses complications correspondantes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
CA2434169C (fr) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
WO2005041962A1 (fr) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
BRPI0620020A2 (pt) 2005-12-22 2011-10-25 Takeda Pharmaceutical preparação sólida, e, partìcula revestida

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (fr) * 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiaxolidinedione hypoglycemiques
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (fr) * 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
DE69211450T2 (de) * 1991-08-16 1996-12-05 Sandoz Ag Inhalator zur Verabreichung von pulverförmigen Substanzen
ES2101866T3 (es) * 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
CN1264302A (zh) 2000-08-23
AR019331A2 (es) 2002-02-13
GB9715306D0 (en) 1997-09-24
DE69838066T2 (de) 2008-03-20
EA003303B1 (ru) 2003-04-24
KR20010021948A (ko) 2001-03-15
KR100680667B1 (ko) 2007-02-09
CO4940422A1 (es) 2000-07-24
NO20000229D0 (no) 2000-01-17
HUP0003634A2 (hu) 2001-07-30
UY25103A1 (es) 2000-12-29
PE99799A1 (es) 1999-12-22
MY138246A (en) 2009-05-29
ES2290989T3 (es) 2008-02-16
EA200000141A1 (ru) 2000-08-28
JP2001510158A (ja) 2001-07-31
DE69838066T3 (de) 2012-03-29
AU743269B2 (en) 2002-01-24
HK1029272A1 (en) 2001-03-30
SK288053B6 (sk) 2013-03-01
EP0998291B2 (fr) 2011-07-06
IL134045A0 (en) 2001-04-30
ES2290989T5 (es) 2011-11-11
CA2297115C (fr) 2010-02-23
DK0998291T3 (da) 2007-11-05
CY1107745T1 (el) 2013-04-18
IN189035B (fr) 2002-12-07
AR016768A1 (es) 2001-08-01
BR9810904A (pt) 2000-09-26
HU229119B1 (en) 2013-08-28
TR200000135T2 (tr) 2000-05-22
DZ2564A1 (fr) 2003-02-15
ZA986365B (en) 2000-01-17
AP1318A (en) 2004-10-22
WO1999003476A1 (fr) 1999-01-28
NZ520652A (en) 2004-06-25
NO20000229L (no) 2000-01-17
CA2297115A1 (fr) 1999-01-28
SI0998291T1 (sl) 2007-12-31
UA70302C2 (uk) 2004-10-15
EP0998291B1 (fr) 2007-07-11
PL199125B1 (pl) 2008-08-29
SK287823B6 (sk) 2011-11-04
PT998291E (pt) 2007-10-11
HUP0003634A3 (en) 2003-04-28
DE69838066D1 (de) 2007-08-23
OA11632A (en) 2004-11-22
AP2000001734A0 (en) 2000-03-31
BG104139A (en) 2000-11-30
PL338127A1 (en) 2000-09-25
SK602000A3 (en) 2000-07-11
NO326356B1 (no) 2008-11-17
TW586926B (en) 2004-05-11
CZ2000173A3 (en) 2001-05-16
CZ302668B6 (cs) 2011-08-24
BG64892B1 (bg) 2006-08-31
NZ515555A (en) 2002-09-27
NZ501256A (en) 2002-09-27
AU8448798A (en) 1999-02-10
ATE366577T1 (de) 2007-08-15
JP2005247865A (ja) 2005-09-15
ID24198A (id) 2000-07-13
EP0998291A1 (fr) 2000-05-10
SI0998291T2 (sl) 2011-10-28
DK0998291T4 (da) 2011-09-26

Similar Documents

Publication Publication Date Title
FR09C0055I2 (fr) Composition pharmaceutique comprenant de pioglitazone et du glimepiride pour utilisation dans le traitement du diabete
MA26512A1 (fr) Composition pharmaceutique pour une methode de traitement du diabete sucre.
OA09123A (fr) Composition pharmaceutique pour la prévention des maladies sexuellement transmissibles.
DZ2675A1 (fr) Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant.
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
NO993646D0 (no) Tiazol benzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme
FR2732223B1 (fr) Composition pharmaceutique pour administration transdermique
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
BE901667A (fr) Composition analgesique et anti-inflammatoire a base de diphenhydramine, leur preparation et leur utilisation.
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
FR2787789B1 (fr) Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
FR2714594B3 (fr) Structure de diffuseur pour infusion de plantes médicinales.
FR2509613B1 (fr) Medicament a base d'insuline pour le traitement du diabete sucre
OA09441A (fr) "Procédés de préparation de ptéridin-4(3H)-ones, et de compositions médicamenteuses les contenant".
DZ2539A1 (fr) Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.
FR2482588B1 (fr) Composition pharmaceutique pour le traitement du diabete sucre juvenile
MA26522A1 (fr) Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
DE3879102D1 (de) Optisch aktive mesomorphe verbindung und diese enthaltende fluessigkristalline zusammensetzung.
FR2717080B1 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
FR2715656B1 (fr) Procédé de préparation d'anhydride citraconique.